Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program | Zendy

Brendon L. Neuen | Zendy; Toshiaki Ohkuma | Zendy; Bruce Neal | Zendy; David R. Matthews | Zendy; Dick de Zeeuw | Zendy; Kenneth W. Mahaffey | Zendy; Greg Fulcher | Zendy; Qiang Li | Zendy; Meg Jardine | Zendy; Richard Oh | Zendy; Hiddo J.L. Heerspink | Zendy; Vlado Perkovic | Zendy

Open Access

Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program

Author(s) -

Brendon L. Neuen,

Toshiaki Ohkuma,

Bruce Neal,

David R. Matthews,

Dick de Zeeuw,

Kenneth W. Mahaffey,

Greg Fulcher,

Qiang Li,

Meg Jardine,

Richard Oh,

Hiddo J.L. Heerspink,

Vlado Perkovic

Publication year - 2019

Publication title -

journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.451

H-Index - 279

eISSN - 1533-3450

pISSN - 1046-6673

DOI - 10.1681/asn.2019010064

Subject(s) - albuminuria , canagliflozin , medicine , empagliflozin , post hoc analysis , diabetes mellitus , creatinine , type 2 diabetes , urology , endocrinology , renal function , kidney disease

If SGLT2 inhibitors protect the kidneys by reducing albuminuria as hypothesized, people with type 2 diabetes mellitus (T2DM) with higher albuminuria should benefit more.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research